Revolution Medicines reported Phase 3 results showing its oral RAS-targeting drug daraxonrasib significantly improved outcomes for first-line metastatic pancreatic cancer, with reports saying median survival roughly doubled versus standard therapy. The company highlighted the data as “unprecedented” and noted ongoing Phase 3 efforts, including the RASolute 303 trial evaluating daraxonrasib as an initial treatment option for this hard-to-treat disease. Find out more details in 3 news articles below.